Want to see SRXH full AI Analyst Report?
SRXH Stock Chart & Stats
$1.75
-$0.21(-11.67%)
At close: 4:00 PM EDT
$1.75
-$0.21(-11.67%)
Day’s Range― - ―
52-Week Range$0.96 - $42.70
Previous Close$1.59
Volume1.23M
Average Volume (3M)704.38K
Market Cap
$28.26M
Enterprise Value$12.46M
Total Cash (Recent Filing)$49.69M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.14
Next Earnings
May 20, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.91%
Share Statistics
EPS (TTM)-79.04
Shares Outstanding20,184,391
10 Day Avg. Volume746,950
30 Day Avg. Volume704,377
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)22.88
Price to Sales (P/S)1.43
P/FCF Ratio-1.14
Enterprise Value/Market Cap0.44
Enterprise Value/Revenue-0.33
Enterprise Value/Gross Profit-1.02
Enterprise Value/Ebitda-1.77
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)580.8
Revenue Forecast (FY)$109.20M
Bulls Say, Bears Say
Bulls Say
Specialty Pharmacy And Patient Support ModelThe company operates in a specialized healthcare segment where dispensing complex therapies and coordinating access can create recurring service demand. Combining pharmacy fulfillment with authorization and adherence support may deepen relationships with prescribers, payors, manufacturers, and patients over the next several quarters.
Improved TTM Balance Sheet CapitalizationZero reported debt and substantial equity relative to assets reduce near-term solvency pressure and may give management greater flexibility to fund operations or pursue strategic initiatives. This is a meaningful improvement in headline capitalization, even though operating returns remain weak and prior leverage was volatile.
CERo Acquisition May Add Oncology Platform ExposureAcquiring CERo could broaden the company beyond its existing healthcare services base into cellular immunotherapy and oncology development. The proposed debt forgiveness may also reshape the capital structure, while CERo’s clinical program provides a potentially meaningful strategic asset if closing conditions are satisfied.
Bears Say
Deeply Negative Free Cash FlowDeeply negative free cash flow indicates that the business is not currently self-funding after investment and operating requirements. Continued cash burn can force additional financing, restrict strategic flexibility, and make the company more vulnerable if operating cash flow does not become consistently positive.
Persistent Losses And Unstable ProfitabilityRepeated annual losses and substantial margin swings make earnings power difficult to establish and reduce confidence in near-term profitability. Unstable results can constrain reinvestment, weaken the ability to absorb execution setbacks, and leave future performance dependent on a sustained operational improvement.
Convertible Financing Creates Dilution And ConstraintsThe financing structure provides capital but can dilute existing common shareholders when preferred securities convert. Its covenants and investor protections may also limit future financing and capital-allocation choices, while the company’s repeated private placements indicate an ongoing need to access external funding.
SRx Health Solutions News
SRXH FAQ
What was SRx Health Solutions’s price range in the past 12 months?
SRx Health Solutions lowest stock price was $0.96 and its highest was $42.70 in the past 12 months.
What is SRx Health Solutions’s market cap?
SRx Health Solutions’s market cap is $28.26M.
When is SRx Health Solutions’s upcoming earnings report date?
SRx Health Solutions’s upcoming earnings report date is May 20, 2027 which is in 222 days.
How were SRx Health Solutions’s earnings last quarter?
SRx Health Solutions released its earnings results on Aug 13, 2026. The company reported -$0.362 earnings per share for the quarter.
Is SRx Health Solutions overvalued?
According to Wall Street analysts SRx Health Solutions’s price is currently Overvalued.
Does SRx Health Solutions pay dividends?
SRx Health Solutions pays a Notavailable dividend of $0.05 which represents an annual dividend yield of 3.91%. See more information on SRx Health Solutions dividends here
What is SRx Health Solutions’s EPS estimate?
SRx Health Solutions’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SRx Health Solutions have?
SRx Health Solutions has 20,184,391 shares outstanding.
What happened to SRx Health Solutions’s price movement after its last earnings report?
SRx Health Solutions reported an EPS of -$0.362 in its last earnings report. Following the earnings report the stock price went up 4.918%.
Which hedge fund is a major shareholder of SRx Health Solutions?
Currently, no hedge funds are holding shares in SRXH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SRx Health Solutions
SRX Global Inc. develops artificial intelligence (AI)-powered solutions designed to improve decision-making, streamline operations, and strengthen risk management. The company is headquartered in Tampa, Florida.
SRXH Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant improvements in profitability measures, including gross profit margins, net loss, and EBITDA. Revenue growth, particularly in the fourth quarter and international markets, was strong. However, there were challenges such as a decline in annual net revenues and ongoing EBITDA losses. Overall, the company's strategic pivots and financial health improvements contributed to a positive outlook.View all SRXH earnings summariesTechnical Analysis
Grifols SA
―
Scilex Holding Company
―
Organon
―
Citius Oncology
―
MIRA Pharmaceuticals, Inc.
―
Ownership Overview
6.55% Insiders
0.56% Mutual Funds
0.10% Other Institutional Investors
92.20% Public Companies and
Individual Investors